Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 5 6 Next >
News headline image
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.